P117 HbA1C monitoring in patients with cystic fibrosis related diabetes (CFRD) during Covid 19 Pandemic
IntroductionCystic fibrosis (CF) affects the pancreas, particularly the β-cells, leading to cystic fibrosis-related diabetes (CFRD) due to insulin deficiency. There is a lack of UK national guidance on how often HbA1C should be monitored. American Diabetes Association (ADA) recommends HbA1c should b...
Gespeichert in:
| Veröffentlicht in: | Thorax 2021-11, Vol.76 (Suppl 2), p.A130-A130 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A130 |
|---|---|
| container_issue | Suppl 2 |
| container_start_page | A130 |
| container_title | Thorax |
| container_volume | 76 |
| creator | Zafran, M Yousif, M Bhaskaran, D Robinson, J Read, J Keele, A Bateman, K |
| description | IntroductionCystic fibrosis (CF) affects the pancreas, particularly the β-cells, leading to cystic fibrosis-related diabetes (CFRD) due to insulin deficiency. There is a lack of UK national guidance on how often HbA1C should be monitored. American Diabetes Association (ADA) recommends HbA1c should be monitored quarterly for patients with CFRD.1 For most patients with CFRD, the HbA1C treatment goal is |
| doi_str_mv | 10.1136/thorax-2021-BTSabstracts.226 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2594959326</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2594959326</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1316-ccceb812efbcc7ac0d431a2c5d0fd0175ad8d569ba55081f75f64674be348dde3</originalsourceid><addsrcrecordid>eNpNkL1OwzAUhS0EEqXwDpZggCHF146dZCyBUiQkKihz5L9QV21SbJefjYUX5UlIKRJMZ_nOvTofQidABgBMnMdZ6-VbQgmF5GL6IFWIXuoYBpSKHdSDVOQJo4XYRT1CUpIIlol9dBDCnBCSA2Q95CZdfH18jtUQSrxsGxdb75on7Bq8ktHZJgb86uIM6_cQnca1U74NLmBvFzJag42TykYb8Gk5ur88w2b90y_bF2cwFHgiG2OXTh-ivVougj36zT56HF1Ny3Fye3d9Uw5vEwUMRKK1tioHamuldSY1MSkDSTU3pDYEMi5NbrgolOS821BnvBapyFJlWZobY1kfHW_vrnz7vLYhVvN27ZvuZUV5kRa8YFR0VL6l1HL-BwCpNmKrrdhqI7b6L7bqxLJv_dtyug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2594959326</pqid></control><display><type>article</type><title>P117 HbA1C monitoring in patients with cystic fibrosis related diabetes (CFRD) during Covid 19 Pandemic</title><source>Alma/SFX Local Collection</source><creator>Zafran, M ; Yousif, M ; Bhaskaran, D ; Robinson, J ; Read, J ; Keele, A ; Bateman, K</creator><creatorcontrib>Zafran, M ; Yousif, M ; Bhaskaran, D ; Robinson, J ; Read, J ; Keele, A ; Bateman, K</creatorcontrib><description>IntroductionCystic fibrosis (CF) affects the pancreas, particularly the β-cells, leading to cystic fibrosis-related diabetes (CFRD) due to insulin deficiency. There is a lack of UK national guidance on how often HbA1C should be monitored. American Diabetes Association (ADA) recommends HbA1c should be monitored quarterly for patients with CFRD.1 For most patients with CFRD, the HbA1C treatment goal is <7% to reduce the risk of microvascular complications.1 We analysed clinical data for all patients with CFRD under Bristol Adult Cystic Fibrosis Centre (BACFC) over 2 years to review HbA1C monitoring in patients with CFRD.ObjectivesReview if HbA1C is measured quarterly.Review if HbA1C target range is achieved.Methods83 cases with known CFRD were included. Retrospective data was collected from CF database and ICE, recorded on excel spread sheet with patient identifiers coded and audited against ADA position statement.ResultsHbA1C value of <7% (<53mmol/mol) was considered as optimal control. In 2019, 16% (N=13/83) had HbA1C measured 3 times a year which dropped to 10% (N=8/83) in 2020. In 2019, 46.98% (N=39/83) had HbA1C checked once a year whereas in 2020 this number was 38.55%(N=32/83). In 2019, 50%(N=42/83) had optimal HbA1C control; the number dropped to 42% (N=35/83) in 2020. Almost half of the patients i.e. 51.8% (N=43/83) and 49.3% (N=41/83) were seen by diabetes team in 2019 and 2020 respectively.Abstract P117 Table 1 S.No Standard/Criteria Results 1 HbA1C measurement is recommended quarterly for patients with CFRD 10%(8/83) 2 For most patients with CFRD, the A1C treatment goal is <7% to reduce the risk of microvascular complications 42%(35/83) ConclusionA small number of our patients had HbA1C checked quarterly and almost half of them had their HbA1C in the target range. Adherence to ADA guidance was reduced during the COVID-19 pandemic in 2020, due to shielding and reduced face to face clinics. Almost half of the patients were seen by diabetes team and this number was not changed in 2020, although the reviews were not face to face. Action plan devised to improve service and develop a local guideline.Developing a national guideline for CFRD monitoring should be considered, taking in to account newer technologies for diabetes monitoring.ReferenceA Position statement of the American Diabetes Association and a Clinical practice guideline of the Cystic Fibrosis Foundation.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thorax-2021-BTSabstracts.226</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>COVID-19 ; Cystic fibrosis ; Diabetes ; Glucose ; Hemoglobin ; Pandemics ; Thinking outside the lung: monitoring and management of patients with CF, PCD and bronchiectasis</subject><ispartof>Thorax, 2021-11, Vol.76 (Suppl 2), p.A130-A130</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Zafran, M</creatorcontrib><creatorcontrib>Yousif, M</creatorcontrib><creatorcontrib>Bhaskaran, D</creatorcontrib><creatorcontrib>Robinson, J</creatorcontrib><creatorcontrib>Read, J</creatorcontrib><creatorcontrib>Keele, A</creatorcontrib><creatorcontrib>Bateman, K</creatorcontrib><title>P117 HbA1C monitoring in patients with cystic fibrosis related diabetes (CFRD) during Covid 19 Pandemic</title><title>Thorax</title><addtitle>Thorax</addtitle><description>IntroductionCystic fibrosis (CF) affects the pancreas, particularly the β-cells, leading to cystic fibrosis-related diabetes (CFRD) due to insulin deficiency. There is a lack of UK national guidance on how often HbA1C should be monitored. American Diabetes Association (ADA) recommends HbA1c should be monitored quarterly for patients with CFRD.1 For most patients with CFRD, the HbA1C treatment goal is <7% to reduce the risk of microvascular complications.1 We analysed clinical data for all patients with CFRD under Bristol Adult Cystic Fibrosis Centre (BACFC) over 2 years to review HbA1C monitoring in patients with CFRD.ObjectivesReview if HbA1C is measured quarterly.Review if HbA1C target range is achieved.Methods83 cases with known CFRD were included. Retrospective data was collected from CF database and ICE, recorded on excel spread sheet with patient identifiers coded and audited against ADA position statement.ResultsHbA1C value of <7% (<53mmol/mol) was considered as optimal control. In 2019, 16% (N=13/83) had HbA1C measured 3 times a year which dropped to 10% (N=8/83) in 2020. In 2019, 46.98% (N=39/83) had HbA1C checked once a year whereas in 2020 this number was 38.55%(N=32/83). In 2019, 50%(N=42/83) had optimal HbA1C control; the number dropped to 42% (N=35/83) in 2020. Almost half of the patients i.e. 51.8% (N=43/83) and 49.3% (N=41/83) were seen by diabetes team in 2019 and 2020 respectively.Abstract P117 Table 1 S.No Standard/Criteria Results 1 HbA1C measurement is recommended quarterly for patients with CFRD 10%(8/83) 2 For most patients with CFRD, the A1C treatment goal is <7% to reduce the risk of microvascular complications 42%(35/83) ConclusionA small number of our patients had HbA1C checked quarterly and almost half of them had their HbA1C in the target range. Adherence to ADA guidance was reduced during the COVID-19 pandemic in 2020, due to shielding and reduced face to face clinics. Almost half of the patients were seen by diabetes team and this number was not changed in 2020, although the reviews were not face to face. Action plan devised to improve service and develop a local guideline.Developing a national guideline for CFRD monitoring should be considered, taking in to account newer technologies for diabetes monitoring.ReferenceA Position statement of the American Diabetes Association and a Clinical practice guideline of the Cystic Fibrosis Foundation.</description><subject>COVID-19</subject><subject>Cystic fibrosis</subject><subject>Diabetes</subject><subject>Glucose</subject><subject>Hemoglobin</subject><subject>Pandemics</subject><subject>Thinking outside the lung: monitoring and management of patients with CF, PCD and bronchiectasis</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpNkL1OwzAUhS0EEqXwDpZggCHF146dZCyBUiQkKihz5L9QV21SbJefjYUX5UlIKRJMZ_nOvTofQidABgBMnMdZ6-VbQgmF5GL6IFWIXuoYBpSKHdSDVOQJo4XYRT1CUpIIlol9dBDCnBCSA2Q95CZdfH18jtUQSrxsGxdb75on7Bq8ktHZJgb86uIM6_cQnca1U74NLmBvFzJag42TykYb8Gk5ur88w2b90y_bF2cwFHgiG2OXTh-ivVougj36zT56HF1Ny3Fye3d9Uw5vEwUMRKK1tioHamuldSY1MSkDSTU3pDYEMi5NbrgolOS821BnvBapyFJlWZobY1kfHW_vrnz7vLYhVvN27ZvuZUV5kRa8YFR0VL6l1HL-BwCpNmKrrdhqI7b6L7bqxLJv_dtyug</recordid><startdate>20211108</startdate><enddate>20211108</enddate><creator>Zafran, M</creator><creator>Yousif, M</creator><creator>Bhaskaran, D</creator><creator>Robinson, J</creator><creator>Read, J</creator><creator>Keele, A</creator><creator>Bateman, K</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20211108</creationdate><title>P117 HbA1C monitoring in patients with cystic fibrosis related diabetes (CFRD) during Covid 19 Pandemic</title><author>Zafran, M ; Yousif, M ; Bhaskaran, D ; Robinson, J ; Read, J ; Keele, A ; Bateman, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1316-ccceb812efbcc7ac0d431a2c5d0fd0175ad8d569ba55081f75f64674be348dde3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>COVID-19</topic><topic>Cystic fibrosis</topic><topic>Diabetes</topic><topic>Glucose</topic><topic>Hemoglobin</topic><topic>Pandemics</topic><topic>Thinking outside the lung: monitoring and management of patients with CF, PCD and bronchiectasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zafran, M</creatorcontrib><creatorcontrib>Yousif, M</creatorcontrib><creatorcontrib>Bhaskaran, D</creatorcontrib><creatorcontrib>Robinson, J</creatorcontrib><creatorcontrib>Read, J</creatorcontrib><creatorcontrib>Keele, A</creatorcontrib><creatorcontrib>Bateman, K</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zafran, M</au><au>Yousif, M</au><au>Bhaskaran, D</au><au>Robinson, J</au><au>Read, J</au><au>Keele, A</au><au>Bateman, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P117 HbA1C monitoring in patients with cystic fibrosis related diabetes (CFRD) during Covid 19 Pandemic</atitle><jtitle>Thorax</jtitle><stitle>Thorax</stitle><date>2021-11-08</date><risdate>2021</risdate><volume>76</volume><issue>Suppl 2</issue><spage>A130</spage><epage>A130</epage><pages>A130-A130</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><abstract>IntroductionCystic fibrosis (CF) affects the pancreas, particularly the β-cells, leading to cystic fibrosis-related diabetes (CFRD) due to insulin deficiency. There is a lack of UK national guidance on how often HbA1C should be monitored. American Diabetes Association (ADA) recommends HbA1c should be monitored quarterly for patients with CFRD.1 For most patients with CFRD, the HbA1C treatment goal is <7% to reduce the risk of microvascular complications.1 We analysed clinical data for all patients with CFRD under Bristol Adult Cystic Fibrosis Centre (BACFC) over 2 years to review HbA1C monitoring in patients with CFRD.ObjectivesReview if HbA1C is measured quarterly.Review if HbA1C target range is achieved.Methods83 cases with known CFRD were included. Retrospective data was collected from CF database and ICE, recorded on excel spread sheet with patient identifiers coded and audited against ADA position statement.ResultsHbA1C value of <7% (<53mmol/mol) was considered as optimal control. In 2019, 16% (N=13/83) had HbA1C measured 3 times a year which dropped to 10% (N=8/83) in 2020. In 2019, 46.98% (N=39/83) had HbA1C checked once a year whereas in 2020 this number was 38.55%(N=32/83). In 2019, 50%(N=42/83) had optimal HbA1C control; the number dropped to 42% (N=35/83) in 2020. Almost half of the patients i.e. 51.8% (N=43/83) and 49.3% (N=41/83) were seen by diabetes team in 2019 and 2020 respectively.Abstract P117 Table 1 S.No Standard/Criteria Results 1 HbA1C measurement is recommended quarterly for patients with CFRD 10%(8/83) 2 For most patients with CFRD, the A1C treatment goal is <7% to reduce the risk of microvascular complications 42%(35/83) ConclusionA small number of our patients had HbA1C checked quarterly and almost half of them had their HbA1C in the target range. Adherence to ADA guidance was reduced during the COVID-19 pandemic in 2020, due to shielding and reduced face to face clinics. Almost half of the patients were seen by diabetes team and this number was not changed in 2020, although the reviews were not face to face. Action plan devised to improve service and develop a local guideline.Developing a national guideline for CFRD monitoring should be considered, taking in to account newer technologies for diabetes monitoring.ReferenceA Position statement of the American Diabetes Association and a Clinical practice guideline of the Cystic Fibrosis Foundation.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><doi>10.1136/thorax-2021-BTSabstracts.226</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0040-6376 |
| ispartof | Thorax, 2021-11, Vol.76 (Suppl 2), p.A130-A130 |
| issn | 0040-6376 1468-3296 |
| language | eng |
| recordid | cdi_proquest_journals_2594959326 |
| source | Alma/SFX Local Collection |
| subjects | COVID-19 Cystic fibrosis Diabetes Glucose Hemoglobin Pandemics Thinking outside the lung: monitoring and management of patients with CF, PCD and bronchiectasis |
| title | P117 HbA1C monitoring in patients with cystic fibrosis related diabetes (CFRD) during Covid 19 Pandemic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A21%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P117%E2%80%85HbA1C%20monitoring%20in%20patients%20with%20cystic%20fibrosis%20related%20diabetes%20(CFRD)%20during%20Covid%2019%20Pandemic&rft.jtitle=Thorax&rft.au=Zafran,%20M&rft.date=2021-11-08&rft.volume=76&rft.issue=Suppl%202&rft.spage=A130&rft.epage=A130&rft.pages=A130-A130&rft.issn=0040-6376&rft.eissn=1468-3296&rft_id=info:doi/10.1136/thorax-2021-BTSabstracts.226&rft_dat=%3Cproquest_bmj_j%3E2594959326%3C/proquest_bmj_j%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2594959326&rft_id=info:pmid/&rfr_iscdi=true |